<DOC>
	<DOC>NCT00118456</DOC>
	<brief_summary>AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against ErbB and VEGF receptor family of tyrosine kinases. It has an IC50 of less than 100 nM against p-EGFR, p-ErbB2, and p-KDR (VEGFR2). This study will assess the safety, pharmacokinetic (PK)/pharmacodynamic (PD) profiles and clinical activity of AEE788 in advanced cancers.</brief_summary>
	<brief_title>Study of Oral AEE788 in Adults With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Histologically confirmed solid tumor Adequate hematologic, renal and hepatic function Age ≥ 18 years Karnofsky performance status score ≥ 70% Life expectancy ≥ 12 weeks Active brain metastases Peripheral neuropathy &gt; grade 2 Diarrhea &gt; grade 1 Gastrointestinal (GI) dysfunction Compromised cardiac function Concurrent severe and/or uncontrolled medical conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Advanced cancers</keyword>
	<keyword>EGFR</keyword>
	<keyword>Her2</keyword>
	<keyword>VEGFR</keyword>
</DOC>